Rosuvastatin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Rosuvastatin
- Rosuvastatin: From Hypercholesterolemia to Cholesterol-Ester Transfer Protein Deficiency
Rosuvastatin: From Hypercholesterolemia to Cholesterol-Ester Transfer Protein Deficiency
One-Sentence Summary
Rosuvastatin is a well-known HMG-CoA reductase inhibitor (statin) globally used to manage hypercholesterolemia and cardiovascular risk, though this Evidence Pack contains no India-specific label or licensing data. The TxGNN model’s top-ranked prediction is Cholesterol-Ester Transfer Protein (CETP) Deficiency, but this is currently supported by 0 clinical trials and only 2 loosely related case-report publications — neither of which studies rosuvastatin directly. Evidence is too thin and mechanistically ambiguous to support this indication at present.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from the India regulatory dataset (no license records); rosuvastatin is globally established as an HMG-CoA reductase inhibitor for hypercholesterolemia/dyslipidemia |
| Predicted New Indication | Cholesterol-Ester Transfer Protein (CETP) Deficiency |
| TxGNN Prediction Score | 99.54% |
| Evidence Level | L5 |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for this candidate is not available in the current Evidence Pack (flagged as a High-severity data gap, DG002). Based on generally known pharmacology, rosuvastatin is a potent HMG-CoA reductase inhibitor that lowers LDL-cholesterol by upregulating hepatic LDL receptors, and it also modestly raises HDL-cholesterol — properties that place it firmly within lipid-metabolism pharmacology.
CETP deficiency, however, is a rare genetic disorder in which loss of cholesteryl-ester transfer protein activity causes markedly elevated HDL-C rather than hypercholesterolemia. This is mechanistically distinct from rosuvastatin’s LDL-lowering action, and the two supporting publications in this pack are case reports on apoA-I deficiency and hepatic lipase deficiency — related rare lipid disorders, but neither is a study of rosuvastatin treatment in CETP deficiency specifically. The link therefore appears to be an artifact of the model’s proximity in “lipid metabolism disorder” concept space rather than a genuine, literature-supported therapeutic hypothesis.
Given the absence of any direct pharmacological or clinical rationale connecting rosuvastatin to CETP deficiency, this prediction should be treated as a low-confidence signal warranting further mechanistic investigation rather than a near-term repurposing opportunity.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21122686 | 2010 | Case report/Review | Journal of Clinical Lipidology | Describes complete Apo A-I deficiency in an Iraqi family with premature atherosclerosis; does not evaluate rosuvastatin or CETP deficiency directly |
| 22798447 | 2010 | Case report | BMJ Case Reports | Describes hepatic lipase deficiency in a Middle-Eastern male, reporting CETP activity/mass as a secondary finding; not a treatment study |
Both papers are tangential to the predicted indication — neither addresses rosuvastatin as a therapy for CETP deficiency.
India Market Information
Rosuvastatin is currently not marketed in India under this dataset, with 0 registered licenses. No product, dosage form, or approved-indication records are available for review.
Safety Considerations
Drug Interactions: The DDI database records 524 total interactions for rosuvastatin. Notable examples from the sampled list include:
- Major: Fenofibrate, Atazanavir
- Moderate: Zidovudine, Paclitaxel, Adalimumab, Trastuzumab emtansine, Ethanol, Alpelisib, Amiodarone, Sodium citrate, Apalutamide, Asparaginase (E. coli / Erwinia chrysanthemi), Atorvastatin, Auranofin, Bempedoic acid, Ezetimibe
- Minor: Levonorgestrel, Norethisterone, Desogestrel
No key warnings or contraindications data are currently available (flagged as a Blocking data gap, DG001 — TFDA label warnings/contraindications). Please refer to the official package insert for complete safety information once available.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication (CETP deficiency) has no direct clinical or mechanistic evidence linking rosuvastatin to this disease — the two supporting publications concern unrelated rare lipid disorders. Combined with a Blocking data gap on TFDA safety labeling (DG001) and a High-severity gap on mechanism of action (DG002), this candidate cannot proceed past initial safety screening (S0).
To proceed, the following is needed:
- Confirmed rosuvastatin mechanism of action (MOA) data from DrugBank
- TFDA/local regulatory label with warnings and contraindications
- Direct preclinical or clinical evidence connecting rosuvastatin to CETP activity or CETP-deficiency-related lipid phenotypes
- Reassessment against alternative, better-supported candidates in this Evidence Pack (e.g., familial hypercholesterolemia, rank 2, which has extensive Phase 3 RCT support, or HIV-related cardiovascular risk reduction, rank 5, L3/S1) as these show substantially stronger evidence bases
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.